[1][2] The development rights to the drug were purchased by Takeda Pharmaceuticals from Ovid Therapeutics in 2021.

The Phase 2 ELEKTRA study indicated that soticlestat was well tolerated and reduced seizure frequency.

[5] In the Phase 3 SKYLINE clinical study, Takadea reported that topline data showed soticlestat plus standard of care narrowly missed its primary endpoint of reducing convulsive seizure frequency in patients with Dravet syndrome.

However, it demonstrated clinically significant effects on several key secondary endpoints, including responder rates and measures of caregiver and clinician global perceptions of improvement.

In the separate Phase 3 SKYWAY trial, soticlestat did not meet its primary endpoint of reducing major motor drop seizures in Lennox–Gastaut syndrome.